Market Overview:
ALK inhibitors are a class of drugs that block the activity of the ALK protein. They are used to treat cancers that have spread (metastasized) to other parts of the body from where they started, such as lung cancer. The first generation ALK inhibitors include crizotinib and ceritinib. The second generation ALK inhibitors include brigatinib, lorlatinib, and alectinib.
Product Definition:
Anaplastic Lymphoma Kinase (ALK) is a protein that is found on the surface of cells. It helps to control the growth and movement of cells. Anaplastic lymphoma kinase inhibitor (ALKi) is a type of drug that blocks the action of ALK. This can help to stop or slow down the growth of cancer cells that have too much ALK activity.
First Generation ALK Inhibitor:
First generation ALK inhibitor (seems like a mouthful) is one of the first-line treatment for patients with metastatic melanoma. It works by blocking the activity of the protein known as MEK, which is responsible for promoting cancer cell growth. The drug has been found to be effective in patients who have developed resistance to traditional chemotherapies such as 5-ALA and Dacogen.
Second Generation ALK Inhibitor:
The Second Generation ALK Inhibitor (SGA) is a type of medication that decreases the production of abnormal cells in the body. The SGA’s work by blocking an important step in cancer cell growth called “the Warburg effect”. This inhibitor has shown to be effective against both Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Application Insights:
The others application segment held the largest share of more than 50.0% in 2017. The segment includes research settings and industrial applications such as biologics production and manufacturing of drugs for human use. In recent years, there has been an increase in the number of research studies that have used anaplastic lymphoma kinase inhibitor for various applications including solid tumors, blood disorders, hematological malignancies and autoimmune diseases. However, retail pharmacy holds a significant market share owing to increasing awareness about cancer treatment among patients along with availability of affordable prices for these drugs in retail pharmacies compared to hospital pharmacies or specialty pharmacies.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Medarex; and Verastem, Inc., which are developing new products for patients with ALK-positive tumors. Moreover, approval of these drugs in U.S. is also one of the major factors driving this regional market over the forecast period. For instance, eryaspase (asparaginase) was approved by FDA in December 2015 for treatment of adults with Philadelphia chromosome-negative relapsed or refractory aggressive lymphoma that is responsive to chemotherapy and radiation therapy or who have undergone prior systemic therapy [1].
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to increasing awareness about various treatment options available for patients suffering from ALK-positive tumors coupled with rising disposable income levels among people affected by this disease [2].
Growth Factors:
- Increasing incidence of anaplastic lymphoma kinase (ALK) positive tumors: The increasing incidence of ALK-positive tumors is the primary growth driver for the global ALK inhibitor market. According to a study by the American Cancer Society, approximately 5%–10% of all non-small cell lung cancers are positive for ALK rearrangements, and this number is estimated to increase in the coming years. This will result in an increased demand for targeted therapies such as ALK inhibitors and drive the growth of the global ALK inhibitor market.
- Growing awareness about targeted therapies: There is a growing awareness among physicians and patients about targeted therapies such as ALK inhibitors. This has led to an increased adoption of these drugs, which is driving the growth of the global ALK inhibitor market.
- Availability of novel therapeutics: The development pipeline for novel therapeutics against cancer is robust, with several promising candidates in various stages of development across different tumor types including non-small cell lung cancer (NSCLC). This will lead to an increased availability of novel therapeutics such as ALK inhibitors and drive their uptake, thereby propellingthegrowthoftheglobalALKinhibitormarketovertheforecastperiod .
Scope Of The Report
Report Attributes
Report Details
Report Title
Anaplastic Lymphoma Kinase ALK Inhibitor Market Research Report
By Type
First Generation ALK Inhibitor, Second Generation ALK Inhibitor, Third Generation ALK Inhibitor
By Application
Hospital Pharmacy, Retail Pharmacy, Others
By Companies
Astellas Pharma, AstraZeneca, Betta Pharmaceuticals, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, Takeda Pharmaceuticals, Turning Point Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
209
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Report Segments:
The global Anaplastic Lymphoma Kinase ALK Inhibitor market is segmented on the basis of:
Types
First Generation ALK Inhibitor, Second Generation ALK Inhibitor, Third Generation ALK Inhibitor
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma
- AstraZeneca
- Betta Pharmaceuticals
- GlaxoSmithKline
- Merck
- Novartis
- Pfizer
- Roche
- Takeda Pharmaceuticals
- Turning Point Therapeutics
Highlights of The Anaplastic Lymphoma Kinase ALK Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- First Generation ALK Inhibitor
- Second Generation ALK Inhibitor
- Third Generation ALK Inhibitor
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anaplastic Lymphoma Kinase ALK Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anaplastic lymphoma kinase (ALK) inhibitors are medications that block the activity of ALK. This can help to treat various types of cancer by stopping the growth and spread of tumors.
Some of the major companies in the anaplastic lymphoma kinase alk inhibitor market are Astellas Pharma, AstraZeneca, Betta Pharmaceuticals, GlaxoSmithKline, Merck, Novartis, Pfizer, Roche, Takeda Pharmaceuticals, Turning Point Therapeutics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Anaplastic Lymphoma Kinase ALK Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Anaplastic Lymphoma Kinase ALK Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Anaplastic Lymphoma Kinase ALK Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Size & Forecast, 2018-2028
4.5.1 Anaplastic Lymphoma Kinase ALK Inhibitor Market Size and Y-o-Y Growth
4.5.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Absolute $ Opportunity
Chapter 5 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Type
5.2.1 First Generation ALK Inhibitor
5.2.2 Second Generation ALK Inhibitor
5.2.3 Third Generation ALK Inhibitor
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Anaplastic Lymphoma Kinase ALK Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Type
9.6.1 First Generation ALK Inhibitor
9.6.2 Second Generation ALK Inhibitor
9.6.3 Third Generation ALK Inhibitor
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Type
10.6.1 First Generation ALK Inhibitor
10.6.2 Second Generation ALK Inhibitor
10.6.3 Third Generation ALK Inhibitor
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Type
11.6.1 First Generation ALK Inhibitor
11.6.2 Second Generation ALK Inhibitor
11.6.3 Third Generation ALK Inhibitor
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Type
12.6.1 First Generation ALK Inhibitor
12.6.2 Second Generation ALK Inhibitor
12.6.3 Third Generation ALK Inhibitor
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Anaplastic Lymphoma Kinase ALK Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Type
13.6.1 First Generation ALK Inhibitor
13.6.2 Second Generation ALK Inhibitor
13.6.3 Third Generation ALK Inhibitor
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Anaplastic Lymphoma Kinase ALK Inhibitor Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Anaplastic Lymphoma Kinase ALK Inhibitor Market: Competitive Dashboard
14.2 Global Anaplastic Lymphoma Kinase ALK Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma
14.3.2 AstraZeneca
14.3.3 Betta Pharmaceuticals
14.3.4 GlaxoSmithKline
14.3.5 Merck
14.3.6 Novartis
14.3.7 Pfizer
14.3.8 Roche
14.3.9 Takeda Pharmaceuticals
14.3.10 Turning Point Therapeutics
